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Abstract: The preoperative diagnosis of pelvic masses has been elusive to date. Methods for characterization such as CA-125 have had limited specificity. We hypothesize that genomic variation
can be used to create prediction models which accurately distinguish high grade serous ovarian
cancer (HGSC) from benign tissue. Methods: In this retrospective, pilot study, we extracted DNA
and RNA from HGSC specimens and from benign fallopian tubes. Then, we performed whole exome
sequencing and RNA sequencing, and identified single nucleotide variants (SNV), copy number
variants (CNV) and structural variants (SV). We used these variants to create prediction models to
distinguish cancer from benign tissue. The models were then validated in independent datasets and
with a machine learning platform. Results: The prediction model with SNV had an AUC of 1.00 (95%
CI 1.00–1.00). The models with CNV and SV had AUC of 0.87 and 0.73, respectively. Validated
models also had excellent performances. Conclusions: Genomic variation of HGSC can be used to
create prediction models which accurately discriminate cancer from benign tissue. Further refining of
these models (early-stage samples, other tumor types) has the potential to lead to detection of ovarian
cancer in blood with cell free DNA, even in early stage.
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1. Introduction
The main reason why ovarian cancer remains one of the most deadly cancers in women
in the United States [1] is because it is diagnosed in an advanced stage in over 70% of
patients, with 5-year overall survival around 40–50% [2]. Patients diagnosed at early stages
have significantly improved 5-year survival exceeding 90%. High grade serous carcinoma
(HGSC) is the most common histologic type of the ovarian cancer spectrum, which includes
fallopian tube, ovarian and primary peritoneal cancers. It is clear that early diagnosis of
ovarian cancer would save lives. Unfortunately, no current method of screening has been
proven effective at detecting ovarian cancer at an earlier stage [3].
Patients with ovarian cancer typically present with a pelvic mass, with or without
symptoms or evidence of metastasis. In those without evidence of metastasis, it is difficult
to determine if the mass is benign or malignant preoperatively. A biopsy of the mass is not
advised as it has the potential to upstage the patient and may not obtain adequate tissue for
diagnosis. Numerous medical organizations and groups have published recommendations
on how to manage these pelvic masses [4–7]. Usually, clinical data, tumor markers and
imaging studies (generally ultrasound) are used. Regrettably, the specificity of these
algorithms varies depending on the utilized methods, and a large proportion of these
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masses are removed surgically, even when found by chance in asymptomatic women. The
current standard to treat any suspicious masses is to surgically remove them, leading to
surgery on a large number of benign masses which could have been safely observed, an
expensive strategy to reduce ovarian cancer mortality. Furthermore, over 10% of these
patients undergoing surgery will experience a major complication [8]. Ovarian cancer
patients treated by trained gynecologic oncologists have improved outcomes over patients
treated by other practitioners [9–12]. Unfortunately, it is estimated that one third of patients
with gynecological malignancies never see a gynecologic oncologist [13]. Therefore, it is
critical to better select patients with a high probability of ovarian cancer to be referred to
trained specialists.
Cancers undergo a myriad of mutations and alterations in their genome during their
development. While these mutations may not cause direct transcriptional or translational
consequences, it is possible to use them to create models that would discriminate cancerous
tissue from benign tissue. To achieve this goal, we leveraged a well annotated biobank of
HGSC and normal fallopian specimens and determined and compared genomic variation of
these samples. The goal of our pilot study was not to perform a comprehensive analysis of
genomic variation, but to assess the feasibility of these variants, no matter how rare [14,15],
to discriminate HGSC from normal tissue. Then, we validated our prediction models of
HGSC with different platforms, independent datasets, and machine learning algorithms.
2. Results
2.1. Single Nucleotide Variation
The workflow for the SNV analysis is represented in Figure 1. SNVs were identified
with the VEP and superFreq methods from DNA of 20 HGSC (cases) and 14 normal
fallopian tube (controls).
2.1.1. VEP Analysis
30,951,598 variants for all samples, located in 11,342,380 unique loci, were identified
in our initial analysis in both the tumor and control specimens. A visual representation
of all SNVs identified from just one sample and the downstream effects of these SNVs
are shown in Supplementary Figure S1. 242,320 loci were also identified in the gnomAD
database (Figure 1) and were removed from the analysis, leaving 11,100,060 unique loci for
model construction. Supplementary Figure S2 shows all SNVs detected in the gnomAD
database with VEP. Multiple univariate analysis of SNVs located in these 11 million loci and
comparing tumor versus control samples resulted in 16,631 SNVs associated with HGSC
that were selected for the multivariate analysis (p < 0.001) (Figure 2A).
2.1.2. superFreq Analysis
220,293. SNVs within 118,839 unique loci were identified in our specimens. 100,164 of
these unique loci were also present in either gnomAD database or the VEP analysis. This
left 18,675 unique loci identified in the superFreq database which were not identified in
the VEP analysis (Figure 1). When comparing cases and controls for SNVs located in these
loci, 5 were found to be below the cut-off level in multiple univariate analyses (p < 0.05)
(Figure 2B). None of these 5 SNVs were informative in the final multivariate model for
HGSC prediction and were discarded, though.
The pathway analysis from the KEGG database was performed with 7151 genes
harboring all 16,636 SNVs identified in both analyses. Significant pathways contain numerous intracellular signaling systems and are depicted in Supplementary Table S1 and
Supplementary Figure S3.
2.1.3. Prediction Modeling
A multivariate lasso regression using selected SNVs from all univariate analyses,
resulted in a model with 49 SNV, with a performance measured in AUC of 1.0 (Figure 3).
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The workflow for the SNV analysis is represented in Figure 1. SNVs were identified
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of over 404 k SNVs for HGSC samples. Over 242,000 of them were already present in normal controls
from the gnomAD database, with no differences in allele frequencies, p-value < 0.05, from more than
125,000 individuals. These were subtracted from the analysis. The resultant SNVs were assessed
for their association with HGSC with multiple univariate logistic regressions. Unrelated controls
consisted in 14 DNA sample from the distal part of the Fallopian tube (fimbria) from patients with
no disease and no family history of ovarian cancer. The analysis resulted in 16,631 selected SNVs,
associated with HGSC, at a p-value < 10−3 . Variation analysis with superFreq. The analysis was
performed in the same cases and controls than before. Of the initial approximately 220 thousand
SNVs found in all HGSC samples after quality filters, 118,839 were in unique loci. Over 100,164 of
them were already present in normal controls from the gnomAD database, or in the previous analysis
with VEP. These were subtracted from the analysis. The resultant 18,675 SNVs were assessed for their
association with HGSC with multiple univariate logistic regressions, as in VEP analysis. 5 significant
SNVs, associated with HGSC were selected, at a p-value 0.05. SNV: single nucleotide variation; HGSC:
high-grade serous ovarian cancer; WES: whole exome sequencing.

2.1.4. Validation in RNA-seq
RNA was extracted and sequenced from 112 patients with HGSC (cases) and 12 fallopian tube specimens (controls). In the VEP analysis of the RNA-seq data, we identified
105,296,475 variants for all samples, located within 3,276,351 unique loci. When compared
to the 11,100,060 unique loci identified in the WES data, 1,254,958 unique loci were common
to both the WES and RNA-seq datasets (Supplementary Figure S4). Of the 16,631 selected
SNVs associated with HGSC from the WES analysis, 6296 of these were also identified in
the RNA-seq data and therefore common to both datasets. Using these common selected
SNVs in the WES set identified in the RNA-seq analysis, multiple univariate regressions
were performed to determine their association with HGSC. 532 were found to be associated
with HGSC (p < 0.05) (Figure 4A). In the multivariate regression analysis, including these
532 SNV, three of these SNVs were independently associated with HGSC, all of which were
protective (Figure 4B). A multivariate lasso regression model to predict HGSC was then
created with all 532 SNV selected in all univariate analyses, resulting in a model with four
SNV with an AUC of 0.99 (95% CI: 0.97–1.00) (Figure 4C).
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superFreq SNV analysis was also performed using the RNA-seq data. However, none
of the SNVs that were present in both the WES and RNA-seq data, but not present in the
VEP analysis, passed the cut-off after initial univariate logistic analyses (Supplementary
Figure S4).
Pathway enrichment analysis was performed with genes harboring the 532 significant
SNVs (Supplementary Table S2). The most significant pathways included the Fox0 pathway
and GnRH signaling pathway (Supplementary Figure S5).
Additionally, we used the TCGA database to further validate our results. When crossreferencing the unique loci in TCGA with the 16,631 identified in the VEP analysis with
WES data, 8427 were common between the two datasets (Supplementary Figure S6). No
further comparisons were possible because of the lack of RNA-seq from controls in the
HGSC TCGA set.
Validation of both models performed with machine learning (TensorFlow) classification with all significant SNV associated with HGSC (N = 16,631) and with SNV from
the multivariate lasso model (N = 49) had an excellent performance, with an AUC of
1.00 (Supplementary Figure S7A,B). These models performed very well without any correction. Models with RNA-seq data also performed well but lower than those with DNA
SNVs (Supplementary Figure S7C,D). The TensorFlow model with UI RNA-seq data, with
20 SNVs present in both DNA and RNA, had and AUC of 0.95, after accounting for unbalanced data (tubes represented less than 10% of the total samples). TCGA RNA-seq model,
with 18 SNV present (out of the initial 49 SNVs from DNA) had an AUC of 0.93, also after
accounting for unbalanced data (we used UI controls to construct the model).

2.1.3. Prediction Modeling
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2.2. Copy Number Variation (CNV)
CNV assessed using superFreq in the DNA WES identified 558 genes (out of the
23,443 genes assessed) that had different CNV between HGSC and controls (Figure 5A).
The multivariate logistic regression determined that 2 of these CNV were independently
associated with HGSC (Figure 5B). A multivariate lasso regression including all 558 significant CNV, resulted in a prediction model with 11 CNV that would predict HGSC with a
performance by AUC of 0.87 (95% CI: 0.72–1.00; Figure 5C). Pathway enrichment analysis
including all significant CNVs yielded one significant pathway, Herpes Simplex Virus
1 infection.
Validation of CNV results using RNA-seq data from UI specimens also was processed with superFreq. The 558 transcripts identified in the WES analysis were assessed
(Supplementary Figure S8A). The validation of the CNV prediction model for HGSC had
an AUC of 0.67 when using RNA-seq data (Supplementary Figure S8B). A lasso prediction
model, independent of the DNA model, and constructed with the 588 significant CNVs
with the RNA-seq data resulted in a prediction model of HGSC with two CNVs and an AUC
of 1.00 (95% CI: 1.00–1.00). One gene significant in the multivariate analysis increased the
risk for cancer and the other decreased the risk for HGSC (Supplementary Figure S8C,D).
In TCGA CGH database, 162 of the 588 CNVs significantly different between cases
and controls in the WES analysis were present (Supplementary Figure S9A). 148 of these
162 were found to be significantly associated with HGSC as compared to normal controls.
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A multivariate lasso regression analysis with all structural variations collectively
identified 17 SV model that predicted HGSC with an AUC of 0.73 (95% CI: 0.69–0.77)
(Supplementary Figure S12).
TCGA validation detected a total of 101,567 SVs in HGSC RNA-seq samples versus
all controls. Out of the 6003 SVs significantly associated with HGSC in the UI analysis,
3429 were present in TCGA set, and 3353 of these were associated with HGSC when
comparing cases versus controls (p < 10−5 ) (Supplementary Figure S13). A multivariate
logistic regression analysis of TCGA significant SVs showed 2 SV independently associated
with HGSC. A new lasso regression analysis was performed with UI data using only those
3429 SVs present in TCGA. It resulted in a prediction model with an AUC of 0.71 (95%
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an AUC of 0.67 when using RNA-seq data (Supplementary Figure S8B). A lasso prediction
model, independent of the DNA model, and constructed with the 588 significant CNVs
with the RNA-seq data resulted in a prediction model of HGSC with two CNVs and an
AUC of 1.00 (95% CI: 1.00–1.00). One gene significant in the multivariate analysis increased the risk for cancer and the other decreased the risk for HGSC (Supplementary
Figure S8C,D).
In TCGA CGH database, 162 of the 588 CNVs significantly different between cases
and controls in the WES analysis were present (Supplementary Figure S9A). 148 of these
162 were found to be significantly associated with HGSC as compared to normal controls.
When a new lasso regression analysis was done in the WES CNV dataset using only CNV
that were present in TCGA (N = 162) the resulting prediction model with 6 CNV had an
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Figure S9B).
2.3. Structural Variation (SV)
In total, there were 250,886 SV of all types detected in the UI RNA-seq when comparFigure
5. Gene
Gene
copy
number
(CNV)
analysis:
there
with
differential
copy
number
ing HGSC
with
normal
tubes
samples
(Figure
6A).
When
comparing
SV counts
for
each
Figure
5.
copy
number
(CNV)
analysis:
therewere
were558
558genes
genes
with
differential
copy
number
−3. (A). Manhattan plot representations of all 558 CNV. The
out
of
all
23,443
genes,
at
a
p-value
<10
−
3
sample
controls,
32,156 <10
were .retained
by MINTIE
significant SVs,
at 558
FDRCNV.
<
out
of allversus
23,443 all
genes,
at a p-value
(A). Manhattan
plot as
representations
of all
red
represent
x2 copies
(or
more than
and
0.5 copieslogistic
(or less than
heterozygous).
(B).
0.05lines
and
at least
log2
fold
(Figure
6B). diploid)
Multiple
univariate
regressions
were perThe
red
lines
represent
x2
copies
(or more
than
diploid)
and 0.5 copies (or
less than heterozygous).
Multivariate logistic regression analysis to determine independently CNV associated with HGSC.
formed to selectlogistic
6003 of
these SVanalysis
associated
with HGSC
for the multivariate
model (Figure
(B).
regression
to model
determine
HGSC.
(C) Multivariate
ROC curve of the multivariate
prediction
withindependently
11 transcripts CNV
with associated
CNV: AUCwith
of 87%,
6C).
75
of
these
SV
were
decreased
in
HGSC
and
5928
were
increased
(Supplementary
(C)
curve of the
multivariate
prediction
model
11 transcripts
CNV: AUC
of 87%,
95%
95%ROC
CI:72%,100%).
All
of them increase
the risk
withwith
relative
moderate with
OR. Below
the ROC
is the
Figure
S10).
Multivariate
analyses
structural
variationsOR.
collectively
well
as for
CI:72%,100%).
All ofname
themand
increase
thefor
riskall
with
relative moderate
Below theas
ROC
is the
table
table
with
transcript
location.
eachtranscript
type of structural
with
name and variation
location. are reported in Supplementary Figure S11.

Validation of CNV results using RNA-seq data from UI specimens also was processed with superFreq. The 558 transcripts identified in the WES analysis were assessed
(Supplementary Figure S8A). The validation of the CNV prediction model for HGSC had
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A multivariate lasso regression analysis with all structural variations collectively
identified 17 SV model that predicted HGSC with an AUC of 0.73 (95% CI: 0.69–0.77)
(Supplementary Figure S12).
TCGA validation detected a total of 101,567 SVs in HGSC RNA-seq samples versus
all controls. Out of the 6003 SVs significantly associated with HGSC in the UI analysis,
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3. Discussion
The overarching goal of this pilot study was to identify genetic/genomic variation
that could differentiate HGSC from normal tubal tissue. With that aim, we used DNA and
RNA sequencing and identified a comprehensive array of genetic/genomic variation in
HGSC and benign fallopian tubes. Then, we used those DNA and RNA characteristics to
create prediction models that would discriminate accurately and robustly, by validating
those models in different settings, in independent databases, in different platforms, and
with different analytics. Our SNV model carried the highest accuracy with an AUC of
1.00 when using 49 different SNV loci, while the models for copy number variation and
structural variation were successful, but somewhat less accurate with AUC of 0.87 and
0.73, respectively. These models were then successfully validated using RNA-seq data from
our dataset as well as TCGA, and the SNV data was even further validated using machine
learning with TensorFlow. Initially, the SNV model is the most promising, but those created
for CNV and SV were not without merit.
The SNV model contained 49 separate loci and had consistently excellent results in all
methods of validation. Some of these variants were associated with a worse prognosis and
some were associated with protection from ovarian cancer, but others have no known effects.
The variants which offered protection from ovarian cancer were more frequent in the normal
samples as compared to the HGSC specimens. This is proof that using infrequent variants
in these specimens and coalescing them into a prediction model is a viable method for
cancer detection, even if these variants are not known to have downstream consequences.
Ovarian cancer, and its most common type HGSC, are commonly diagnosed in advanced stage (75–80%). We built prediction models that would discriminate the most
frequent presenting form of ovarian cancer. The resulting best model also offers the simplest method for reproducibility by others. For these models of HGSC prediction to be
applied clinically, still several steps must be taken. First, they will have to be validated
in prospective manner in a larger sample size to account for potential overfitting that
could occur in retrospective analyses. Should this be successful, then this method could
potentially be used to identify these variants in peripheral blood specimens from circulating
tumor DNA (ctDNA) as a method for ovarian cancer diagnosis. Modifications of these
models would have to be done to account for earlier stages of HGSC and for other rare
forms of ovarian cancer. Adding earlier stages may result in a tool to diagnose all stages of
HGSC. Including other types of ovarian cancer (germ cell, stromal cell types) may result in
a broader detection tool for ovarian cancer. We believe that our study is the first step in
that direction.
It is well known that circulating tumor DNA (ctDNA) and RNA can be isolated from
peripheral blood draws in patients. Circulating tumor DNA is identifiable in ovarian cancer
patient plasma with reliable accuracy, and SNV, CV, and SV have all been identified in
peripheral specimens [16–19]. Conceivably, it is feasible to identify the variations used in
the models through a peripheral blood draw on patients with pelvic masses of unknown
etiology. ctDNA could then be amplified and the necessary variants identified using a predefined panel. ctDNA is a better medium for this type of testing because it is more stable in
an extracellular form than RNA, though circulating tumor RNA has also been identified and
sequenced. This constitutes a method to diagnose ovarian cancer with a “liquid biopsy”.
ctDNA has been identified in ovarian cancer patients at early stages [20]. Panels for other
cancers have been created to drive individualized treatment, cancer surveillance, and early
diagnosis; two of which have recently gained FDA approval [21,22]. Given that ovarian
cancer ctDNA is identifiable in patients with early-stage ovarian cancer, and that our model
predicts ovarian cancer with high accuracy, the model described here has the potential to
provide a strong diagnostic tool for ovarian cancer at an early-stage.
Additionally, this method could be used to identify recurrent or persistent cancer
in patients who have completed their adjuvant therapy. Liquid biopsy has already been
shown to be feasible in identifying recurrence in ovarian cancer and these methods are
currently being investigated in the monitoring of lung cancer [23,24]. While these would
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likely require different models to identify those variations which are present in recurrent
cancer, the methods for creating them would be the same.
The current methods for pre-operative characterization of pelvic masses leave significant room for improvement. A method with little to no false negative or positives would
allow us to triage referrals to gynecologic oncologists appropriately, maximizing their
efforts while keeping benign patients with their trusted gynecologists to either proceed
with surgery for symptomatic masses or avoid surgery altogether for asymptomatic masses.
This would lower the costs for surgery, referrals to specialists, and minimize risk to patients
with benign masses.
The strengths of this study are a thorough analysis of all possible SNVs, CNVs and SVs
in well annotated patients with HGSC and an adequate number of appropriate controls.
These results were validated in independent datasets (TCGA), with different platforms
(CGH, RNA-seq), and different analytical platforms maintaining acceptable performances.
By analyzing different types of genomic variations, we were able to increase the chances
that we could create an accurate prediction model. Some of the limitations of our study
is that the specimens used were from advanced HGSC and benign fallopian tubes. While
this allowed us to obtain a greater number of specimens and compare them to truly benign
tissue, it limits our ability to apply these results to early-stage disease and other types of
ovarian cancer. Continued efforts collecting more specimens of varied stages, histologies,
increasing the racial diversity of our specimens, and adding more rare variants, will further
improve the accuracy and generalizability of the prediction model.
4. Materials and Methods
We performed a single institution, retrospective, pilot study using tumor specimens
obtained at the time of cytoreductive surgery from 112 patients with HGSC and compared
them to benign fallopian tube specimens from 14 patients collected at the time of surgery
for benign indications. DNA and RNA were isolated from all specimens and whole exome
sequencing (WES) and RNA sequencing (RNA-seq) were performed. Using this WES
and RNA-seq data, single nucleotide variants (SNV), copy number variation (CNV) and
structural variation (SV) were identified. As mentioned before, the goal was not to perform
a comprehensive analysis of genomic variation, but to assess the feasibility of these variants
to discriminate HGSC from normal tissue.
Genetic variations, including somatic and germline mutations, were identified initially
from WES performed in DNA extracted from 20 HGSC specimens and 14 normal Fallopian
tubes specimens. Differences between variants from HGSC and tubes were assessed. Since
tumor tissue was compared to non-matched control tissue, germline variants could not
be identified separately from somatic variations. Then, models to predict HGSC were
constructed using multivariate lasso regression analysis with variants that were different
between HGSC and tubes. These models were then validated with RNA-seq data from all
112 HGSC cases and 12 of the controls (tubes), and with RNA-seq from The Cancer Genome
Atlas (TCGA) database (all HGSC, N = 376). Prediction models were further validated
using machine learning algorithms with TensorFlow.
4.1. Specimen Acquisition
HGSC tissue samples and clinical outcome data were obtained from the Department of
Obstetrics and Gynecology Gynecologic Oncology Biobank (IRB, ID#200209010), which is
part of the Women’s Health Tissue Repository (WHTR, IRB, ID#201804817). All specimens
archived in the Gynecologic Oncology Biobank (herein termed Biobank) were originally
obtained from adult patients under written, informed consent in accordance with University
of Iowa (UI) IRB guidelines. Tumor samples were collected, reviewed by a board-certified
pathologist, flash-frozen, and then the diagnosis was confirmed in paraffin at the time of
initial surgery. All experimental protocols were approved by the University of Iowa (UI)
Biomedical IRB-01.
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We then collected fallopian tube samples from women undergoing gynecologic procedures. Fallopian tubes were obtained from patients with no family history of cancer beside
squamous cell carcinoma of the skin and who were undergoing salpingectomy for benign
indications (mainly sterilization). Fallopian tubes were chosen as controls as this is the most
likely origin of HGSC [25]. DNA and RNA were extracted from epithelial tissue coming
from the junction of the ampullary and fimbriated end of fallopian tubes. Twenty normal
fallopian tube specimens were obtained. Of those, 12 produced viable RNA for analysis.
RNA from both the fallopian tube and HGSC specimens had already been extracted and
purified in a previous study [26]. WES was performed on 14 fallopian tube specimens.
483 patients with serous ovarian cancer were identified in the database. Only patients
with a primary diagnosis of advanced Stage (III and IV) HGSC were included. Of these,
112 patients with fresh frozen specimens were selected for RNA isolation and genomic
analysis, as described previously [27]. 20 patients with specimens with high quality DNA
were also selected for WES to perform variation analysis.
4.2. DNA Sequencing
Genomic DNAs (gDNAs) were purified from frozen tumor and fallopian tube tissues
using the DNeasy Blood and Tissue Kit according to manufacturer’s (QIAGEN) recommendations. Yield and purity were assessed on a NanoDrop Model 2000 spectrophotometer and
by horizontal agarose gel electrophoresis. Whole exome sequencing (WES) was performed
externally by GeneWiz (Azenta, Chelmsford, MA, USA) with 100× coverage. Mean quality
score was 37.76 and the percent of bases greater than or equal to 30 was 89.96.
4.3. RNA Sequencing
RNA was isolated from the tumor and control specimens in the Biobank. RNA
extraction, processing and sequencing have been described previously [27,28]. In brief,
total cellular RNA was extracted from primary tumor tissue using the mirVana (Thermo
Fisher, Waltham, MA, USA) RNA purification kit. The RNA yield and quality were assessed
with Trinean Dropsense 16 spectrophotometer and Agilent Model 2100 bioanalyzer. RNA
quality was determined to be adequate if the sample had an RNA integrity number (RIN)
of 7.0 or greater. Samples that were of adequate quality were then sequenced. 500 ng of
RNA was quantified by Qubit measurement (Thermo Fisher). RNA was then converted to
cDNA and ligated to sequencing adaptors with Illumina TriSeq stranded total RNA library
preparation (Illumina, San Diego, CA, USA). cDNA samples were then sequenced with the
Illumina HiSeq 4000 genome sequencing platform using 150 bp paired-end SBS chemistry.
All sequencing was performed at the Genome Facility at the University of Iowa Institute of
Human Genetics (IIHG).
4.4. Single Nucleotide Variation (SNV) Analysis
DNA from WES was aligned to the human reference genome (version hg38) using
Subread. BAM files resulting from the alignment were used with samtools [29] and VarScan
software [30] to create Variant Call Format (VCF) files for further analysis, as recommended
by best practices of genome sequencing [31]. Two separate methods were used to identify
all possible SNV’s present in VCF files. The first method used was the Ensembl Variant
Effect Predictor (VEP). This method determines if variants cause significant downstream
changes in the genome [32]. Variants present upstream of transcripts, coding regions, regulatory regions, non-coding RNA, and that have downstream consequences (i.e., missense,
frameshift, stop gained or lost) are retained and inconsequential variants are removed.
VEP is able of identifying rapidly 4–5 million variants (all types, including SNPs) present
in a typical sequenced genome [32,33]. A table with present SNVs for all samples was
constructed and used for analyses.
In parallel, VCF files were processed with superFreq package to detect other novel
SNVs [34]. This package uses a series of filters to discard SNV with lesser quality. Additionally, SNV detected by superFreq that were present in the gnomAD database were removed.
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SuperFreq assessed SNV in each transcript of each sample and performed a log-ratio of
transcripts with versus without SNV within that sample. That logRatio was used later for
further comparative analyses.
All unique loci containing those SNV’s by both methods were codified.
To identify those SNV unique in HGSC we subtracted all common SNV present in a
large, publicly available database, gnomAD, from SNV results from both VEP and superFreq (Figure 1). The gnomAD database (gnomad.broadinstitute.org) is a database containing 125,748 WES from various studies, aggregated by researchers worldwide [35]. Multiple
univariate logistic regression analyses with each of the resulting SNVs were performed
to identify those variants more informative for cancer (HGSC, a dichotomous dependent
variable, y). The goal was to reduce the number of variables to be introduced in the multivariate prediction analysis to build a classifier, as recommended [36]. Independent variables
(x) were the presence (or absence) of a particular SNV. The cut-off level was established
at a p-value < 0.001. Using the variants identified in these multiple univariate analyses,
an enrichment pathway analysis was performed using the clusterProfiler R package [37],
which interrogates the KEGG database (https://www.genome.jp/kegg/pathway.html,
accessed on 31 December 2021). Significance at the p-value level of < 0.05 were corrected
for multiple comparisons using false discovery rate (FDR). Variants selected with these
univariate analyses were included in a multivariate lasso regression analysis to create
prediction models of HGSC. Performance of all prediction models were measured by the
area under the curve (AUC).
Validation was performed in two different datasets: with RNA-seq data from UI
specimens and with RNA-seq data downloaded from The Cancer Genome Atlas (TCGA).
UI RNA-seq data was also aligned to the human reference genome (version hg38) with
the STAR suite. As before, BAM files were used to create VCF files with samtools and
VarScan, and SNVs were detected with both VEP and superFreq. SNVs from RNA-seq data
were compared to those identified in DNA through WES. Only SNVs from the RNA-seq
experiments that were present and selected in WES multiple univariate logistic analyses of
HGSC versus normal tubes were used for validation analysis. These common SNVs were
assessed for their association with ovarian cancer (HGSC) in multiple univariate logistic
models (cut-off, p-value < 0.05). As before, selected SNVs in univariate analyses were
used to create a prediction model of HGSC in the multivariate lasso regression analysis
(Supplementary Figure S4). In addition, pathway enrichment analysis using the KEGG
database was performed with these selected SNVs in the univariate analysis.
After permission was granted to access controlled data by the Genomic Data Commons
(GDC) Data Portal (dbGaP# 29868), TCGA HGSC BAM files from RNA-seq experiments
aligned to the human reference genome (version hg38) with the STAR suite were downloaded in their original format. TCGA contains RNA-seq data but lacks RNA-seq from
normal tubal samples. We were able, though, to create VCF files from original TCGA BAM
files. SNVs were identified by performing VEP and superFreq analyses, in the same way as
the WES analysis. Then, these SNVs were compared to those present and associated with
HGSC in the WES analysis (Supplementary Figure S6).
To further validate the analysis, we performed the prediction analysis in a machine
learning platform. For that purpose, we used TensorFlow [38] in a Jupyter notebook with
a Keras application programming interface (API) [39]. TensorFlow code was modified
from a tutorial (found here: https://www.tensorflow.org/tutorials, accessed on 2 February
2022). Several models were tested in this platform: first, the model with all SNV associated
with HGSC, the model resulting from the multivariate analysis with lasso, the model for
the validation with IU RNA-seq SNVs, and the model for the validation with RNA-seq
extracted from TCGA. We used classification machine learning approaches to discriminate
tube versus HGSC. Training and testing were performed to account for weights of the
outcomes as well as for unbalanced data (fewer controls than cases for both DNA and
RNA samples).
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4.5. Copy Number Variant (CNV) Analysis
Resulting DNA WES files from the Subread alignment (BAM) were assessed for copy
number variations using superFreq [34]. Once CNV were detected, a univariate logistic
regression was carried out to identify those CNV more informative for HGSC, with a
cut-off p-value of <0.001. Enrichment pathway analysis was performed with genes that
had significant CNV differences in the univariate analysis using clusterProfiler and the
KEGG database. Significance was at a FDR < 0.05. Then, two multivariate analyses were
performed with the significant CNV: (1) multivariate regression additive model to identify
CNV independently associated with HGSC; (2) multivariate lasso regression analysis to
identify which CNV predicted HGSC.
Validation was performed in two independent RNA-seq experiments. First, we identified CNV in the RNA-seq database from the UI with superFreq. The CNVs found to
be significant in the univariate analysis of the DNA WES were assessed in the resulting
RNA-seq CNV data. A lasso prediction model was created with these CNV resulting from
the RNA-seq data, to validate the prediction model created with the significant CNV in the
WES dataset. Additionally, a new multivariate lasso prediction model was created with the
RNA-seq data, independent of the initial WES model, and their respective performances
were compared. Finally, a multivariate logistic regression of the significant CNV from the
WES data was performed in the RNA-seq data, to identify independently significant CNV.
The second validation was performed in TCGA HGSC database. Level 3, or segmentation files, resulting from TCGA HGSC dataset initial array comparative genomic
hybridization experiments (CGH) were downloaded, as detailed previously [40]. This
database was chosen because it has matched normal samples for the comparison. Circular binary segmentation was used to identify regions with altered copy number in each
chromosome [41]. The copy number at a particular genomic location was computed based
on the segmentation mean log-ratio data. The database was first assessed for the presence
of significant CNV in the original, WES univariate analyses. With the resulting CNV new
multiple univariate analyses were performed to determine which had significant changes
in their copy number (p-value < 0.05), represented by their mean log-ratio. Using the
genes with CNV present in the TCGA database, a new lasso prediction model was created
with WES data, and then validated in this new TCGA data. Finally, a multivariate logistic
analysis of all CNV present in TCGH CGH arrays and WES data was carried out to identify
independently CNV associated with HGSC.
4.6. Structural Variation (SV) Analysis
RNA-seq data from UI database (both tumor specimens and controls) was used to
assess structural variation using MINTIE [42]. RNA-seq data was used because rearrangements can be more reliably identified in the transcriptome, especially fusion transcripts [43].
MINTIE is an integrated pipeline for RNA-seq data that takes a reference-free approach,
combining de novo assembly of transcripts with differential expression analysis to identify
up-regulated novel variants in a case–control setting. Counts for each SV in each sample
are compared with counts in all controls with the edgeR package. Then, significant SVs,
with a false discovery rate (FDR) < 0.05 and log2 fold change >2 are retained, after which
the transcripts are aligned to the genome and used for further analyses. Finally, SV counts
are normalized, log transformed and used for univariate logistic regressions. SVs with
differential expression (p-value < 0.001) were then selected and introduced in multivariate
analyses, in an additive model first, to identify independently significant SV for HGSC, and
in a lasso regression model later to identify predictors of HGSC. Significant variations were
classified into type: fusion genes, alternative splicing, deletions, extended exons, intragenic
rearrangement, insertion, novel exon, retained intron, novel exon, novel exon junction, and
partial novel junction.
Validation was then performed in TCGA RNA-seq data and using UI RNA-seq from
UI fallopian tubes for controls, because MINTIE does not need to run on matched normal
tissues or controls. Initially, BAM files were converted to fastq files with bedtools for the

Int. J. Mol. Sci. 2022, 23, 14814

13 of 15

analysis [44]. Then, MINTIE was used to identify all SVs in TCGA dataset. SVs significant in
the UI dataset that were also present in TCGA were used for validation. Briefly, significant
SVs in the comparison of normalized counts for each SV in each sample versus counts in all
controls (corrected p-value with FDR < 10− 5 ) were introduced in multivariate analyses, in
an additive model first, to identify independently significant SV for HGSC, and in a lasso
regression model later to validate UI predictors of HGSC. For this validation, we selected
only those SVs that were present in both UI and TCGA databases: (a) first we constructed a
prediction model of HGSC with lasso regression in the UI database with these common
SVs; (b) then we validated the prediction model created in UI with TCGA data.
5. Conclusions
In this retrospective, feasibility pilot study, we identify a set of genomic variation
(SNV) that can discriminate HGSC with high performance. This effort could be the first step
to a detection tool for ovarian cancer in serum, potentially even in early stages. The final
set of markers could be used to build a DNA genotyping chip, similar to other commercial
DNA tests, where the patient to be tested could send a DNA sample by mail and would get
her results in a couple of weeks.
6. Patents
A patent with the 49 SNVs resulting from the prediction model of HGSC is being
completed at the time of this publication.
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